Table 2:

Adverse effects experienced by study participants

	Relamorelin (n=8)	Placebo (n=12)	p-value
Injection site ecchymoses, bruising, erythema	4 participants (50%)	4 participants (33.3%)	0.65
Electrolyte abnormalities	2 participants (25%)	4 participants (33.3%)	0.99
Dizziness
-All participants	5 participants (62.5%)	1 participant (8.3%)	0.02
-Participants not reporting symptom at baseline	3 participants (50%)	0 participants (0%)	0.03
Fatigue
-All participants	7 participants (87.5%)	5 participants (41.7%)	0.07
-Participants not reporting symptom at baseline	2 participants (66.7%)	2 participants (25%)	0.49
Abdominal pain/cramping
-All participants	7 participants (87.5%)	9 participants (75%)	0.62
-Participants not reporting symptom at baseline	1 participant (50%)	3 participants (60%)	0.99
Muscle weakness
-All participants	1 participant (12.5%)	2 participants (16.7%)	0.99
-Participants not reporting symptom at baseline	1 participant (12.5%)	1 participant (9.1%)	0.99
Hyperhidrosis
-All participants	2 participants (25%)	1 participant (8.3%)	0.54
-Participants not reporting symptom at baseline	1 participant (14.3%)	0 participants (0%)	0.41